Wiener klinische Wochenschrift
-
Wien. Klin. Wochenschr. · Sep 1997
Multicenter Study Clinical TrialPhase II trial of gemcitabine in advanced non-small-cell lung cancer.
Gemcitabine has shown activity in different solid tumors. In the present study we have evaluated its efficacy in 32 patients with advanced non-small-cell lung cancer in a phase II trial. Gemcitabine (1250 mg/m2) was given intravenously as a 30-minute infusion on days 1, 8 and 15. ⋯ Improvement of symptoms occurred in 54% of the patients. Side effects were mild and included predominantly leukopenia and thrombocytopenia. In conclusion, gemcitabine is active and well tolerated in patients with advanced non-small-cell lung cancer.